Form 4: Monopar Therapeutics CEO Chandler Robinson Reports Stock Transactions
SEC Form 4
Chandler Robinson, CEO of Monopar Therapeutics, reports the acquisition of shares through vesting of restricted stock units and the withholding of shares for tax obligations.
Summary
- Chandler Robinson, the CEO of Monopar Therapeutics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On June 30, 2024, Robinson acquired 24,476 shares of common stock through the vesting and settlement of restricted stock units.
- Also on June 30, 2024, 8,684 shares were withheld by Monopar to cover withholding taxes related to the vesting of these restricted stock units at a price of $0.731.
- Following these transactions, Robinson directly owns 265,922.8 shares of Monopar common stock.
- Robinson also indirectly controls 4,111,272.88 shares through Tactic Pharma LLC, which in turn controls TacticGem LLC, and 166,667 shares directly owned by Tactic Pharma LLC; however, he disclaims beneficial ownership except to the extent of his pecuniary interest.
- The reported transactions are related to restricted stock units granted on January 26, 2021 (63,060 units), February 2, 2022 (159,522 units), and February 1, 2023 (169,012 units), which vest in installments.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine stock transactions related to executive compensation.
Positives
- The vesting of restricted stock units suggests continued alignment of the CEO's interests with those of the shareholders.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's prospects.
Comparison to Industry Standards
- Monitoring insider transactions is a standard practice in financial analysis.
- Comparing the vesting schedules and terms of restricted stock units to those of peer companies can provide insights into Monopar's compensation practices.
- Companies like Amgen, Gilead, and Biogen are often benchmarks for compensation structures in the biotechnology industry.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect the ongoing compensation structure for the CEO.
- Employees holding similar stock units will experience similar vesting events.
Key Dates
| Date | Description |
|---|---|
| January 26, 2021 | Grant date of 63,060 restricted stock units. |
| February 2, 2022 | Grant date of 159,522 restricted stock units. |
| February 1, 2023 | Grant date of 169,012 restricted stock units. |
| June 30, 2024 | Date of stock acquisition and tax withholding. |
| July 02, 2024 | Date of filing. |
| December 31, 2024 | Full vesting date of restricted stock units granted on January 26, 2021. |
| December 31, 2025 | Full vesting date of restricted stock units granted on February 2, 2022. |
| December 31, 2026 | Full vesting date of restricted stock units granted on February 1, 2023. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.